Pharmacological modulation of genome and proteome alterations in mice treated with the endocrine disruptor bisphenol

Alberto Izzotti1, Mariagrazia Longobardi, Cristina Cartiglia

  • 1Department of Health Sciences, University of Genoa, Via A. Pastore 1, I-16132 Genoa, Italy.

Insights

The chemopreventive agent phenethyl isothiocyanate (PEITC) partially reduced bisphenol A (BPA)-induced DNA damage in mice, while budesonide (BUD) was ineffective. Proteome analysis revealed BPA altered key cellular processes, and neither agent fully restored normal function.

Area of Science:

  • Endocrinology
  • Toxicology
  • Molecular Biology

Background:

  • Bisphenol A (BPA) is a widespread environmental endocrine disruptor with known genotoxicity.
  • Previous studies showed BPA induces DNA adducts in mouse liver and mammary tissue.
  • Chemopreventive agents are explored for mitigating BPA's adverse effects.

Purpose of the Study:

  • To evaluate the efficacy of budesonide (BUD) and phenethyl isothiocyanate (PEITC) in modulating BPA-induced DNA adducts and proteome alterations.
  • To assess the potential of proteome analysis for predicting chemopreventive agent efficacy and adverse effects.

Main Methods:

  • Swiss ICR (CD-1) mice were administered BPA orally and either BUD or PEITC via diet for 8 days.
  • DNA adducts were quantified using (32)P postlabeling.
  • Proteome alterations were analyzed using antibody microarrays targeting 656 proteins.

Main Results:

  • BPA induced similar DNA adduct formation in liver and mammary tissues.
  • BPA dysregulated 13 proteins in mammary tissue, including estrogen receptor-beta, affecting cell proliferation, apoptosis, and stress response.
  • PEITC significantly inhibited BPA-induced DNA adducts at the highest dose; BUD showed no effect.
  • Both agents modulated BPA-induced proteome changes, but neither fully restored physiological conditions.

Conclusions:

  • PEITC demonstrated partial chemopreventive activity against BPA-induced genotoxicity.
  • Proteome analysis is a sensitive tool for evaluating both the protective and adverse effects of chemopreventive agents in vivo.
  • Neither BUD nor PEITC fully reversed BPA-induced molecular disruptions in the tested model.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Genomic Imprinting and Inheritance02:30

Genomic Imprinting and Inheritance

Diploid organisms inherit genetic material through chromosomes from both parents. Copies of the same gene are known as alleles. In most cases, both alleles are simultaneously expressed and allow various cellular processes to function optimally. If one of the alleles is missing or mutated, the expression of the other allele can compensate; however, this is not true for all genes.
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.